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The bactericidal activity (BA) of cefadroxil, a semisynthetic cephalosporin antibiotic, against
M. tuberculosis H37Rv was studied in Middlebrook 7H9 medium, Cefadroxil showed good BA (average
fall of viable counts = log10 0.32 colony forming units/ml/day) against the log phase culture of M.
tuberculosis H37Rv. Its minimal inhibitory concentration (MIC) and minimal bactericidal concentra-
tion (MBC) were found to be 15 µg/ml or less. The MIC of cefadroxil for 29 clinical isolates of M.
tuberculosis and a laboratory strain, M. tuberculosis H37Rv was also determined by agar dilution
method using Middlebrook 7H11 agar as a screening procedure. The MIC of cefadroxil was found
to be 10 µg/ml or less for M. tuberculosis H37Rv and 16 (55.1%) of 29 clinical isolates tested. The MIC
for 3 of 10 drug sensitive and 9 of 19 drug resistant isolates was 40 or more, a concentration much
higher than the peak plasma concentration (28 µg/ml) attained in human beings. The higher MIC
observed in 12 of 29 clinical isolates irrespective of their susceptibility pattern requires further studies
to assess the usefulness of cefadroxil in the treatment of tuberculosis.
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Multi-drug resistant tuberculosis (MDR-TB) is
being frequently reported1. Failure to cure MDR-TB
with the currently available drugs might result in its
spread in the community. There is therefore an ur-
gent need to identify new and potent drugs to effec-
tively treat such patients and thereby interrupt the
chain of transmission in the community.
Cefadroxil is a semisynthetic cephalosporin anti-
biotic active against Gram-positive and Gram-nega-
tive bacteria. It is resistant to inactivation by the
beta-lactamases produced by these bacteria2 and is
highly bactericidal with low toxicity. Cefadroxil can
be administered orally. The peak plasma concentra-
tion attained after single doses of 500 and 1000 mg
are 16 and 28 µg/ml, respectively. Measurable levels
are present up to 12 h after the administration of the
drug. The drug has a very low urinary excretion rate;
absorption is not affected by simultaneous intake of
food; and is widely distributed in body tissues. The
drug can be administered twice or even once a day3.
As these pharmacokinetic characteristics of cefadroxil
are promising, a study was undertaken to determine
the in vitro susceptibility of clinical isolates of M.
tuberculosis to cefadroxil.
Material & Methods
Strains : Clinical isolates of M. tuberculosis were
obtained from the patients attending the Tuberculo-
sis Research Centre, Chennai. A total of 29 isolates
were selected including 10, which were sensitive to
streptomycin, isoniazid, rifampicin and ethambutol
and 19 which were resistant to one or more of these
drugs. The laboratory reference strain M. tuberculo-
sis H37Rv was included as control. All the clinical
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isolates and the reference strain were coded before
setting up the drug susceptibility test.
Bactericidal activity (BA) of cefadroxil against
M. tuberculosis H37Rv : BA was studied by the pro-
cedures described by Dickinson and Mitchison4. In
brief, the log phase culture of M. tuberculosis in
Middlebrook 7H9 liquid medium (Difco, USA) was
adjusted to contain 106 bacilli per ml of fresh me-
dium and cefadroxil (Lupin, India) was added to a
final concentration of 15 and 30 µg/ml. The viable
counts were estimated on days 0, 3 and 7 by inocu-
lating serial 10 fold dilutions of the culture on
Lowenstein-Jensen (LJ) medium. The drug free me-
dium served as control. The growth was recorded at
the end of 4 wk and expressed as log,, colony form-
ing units (cfu)/ml.
BA was defined as the average fall of viable counts
in log10 cfu per ml of culture per day when exposed
to the given concentration of the drug for 7 days5.
Minimal bactericidal concentration (MBC) was
defined as the lowest concentration of the drug which
killed more than 99 per cent of the bacterial popula-
tion in the initial inoculum.
Screening of clinical isolates against cefadroxil :
The clinical isolates of M. tuberculosis were screened
for their susceptibility to cefadroxil by the agar di-
lution method as described by Canetti et al 6. In brief,
the log phase culture of M. tuberculosis  in
Middlebrook 7H9 liquid medium was diluted to
contain 106 bacilli per ml and 0.1 ml of serial 10 fold
dilutions of the culture suspension were inoculated
onto drug-free and drug containing Middlebrook
7H11 agar (Difco, USA) plates. The concentration of
cefadroxil tested ranged from 5 to 40 µg/ml. Viable
counts were estimated after 4 wk of incubation at
37°C.
Minimal inhibitory concentration (MIC) was defined
as the lowest concentration of drug which inhibited
more than 99 per cent of the population in control
culture.
Results & Discussion
The viable counts of M. tuberculosis H37Rv in
7H9 liquid medium without and with different con-
centrations of cefadroxil on days 0, 3 and 7 are
shown in Table I. It can be seen that cefadroxil has
bactericidal activity of 0.3 1, 0.32, respectively with
15 and 30 µg/ml. MIC/MBC was found to be less
than 15 µg/ml which is much below the peak plasma
level (28 µg/ml) attained in man. On the basis of
these results, the susceptibility of clinical isolates of
M. tuberculosis to cefadroxil was determined by agar
dilution method using Middlebrook 7H11 agar me-
dium as a screening procedure.
The distribution of MIC of cefadroxil for clinical
isolates of M. tuberculosis and the reference strain is
given in Table II. The MIC for the reference strain
was found to be 10 µg/ml or less when tested on 6
occasions. The MIC for 7 of 10 drug sensitive iso-
lates and 9 of 19 drug resistant isolates was also
found to be 10 µg/ml or less. However, 3 of 10 drug
sensitive isolates and 9 of 19 drug resistant isolates
were inhibited only at 40 µg/ml or more implying
resistance to cefadroxil. The higher MIC required to
inhibit these strains, was thought to be due to the
inactivation of cefadroxil by the beta-lactamases
produced by M. tuberculosis as several species of
mycobacteria are known to produce different types
of beta-lactamases7. We tested the inactivation of
cefadroxil by substituting cefadroxil as a substrate to
Table I. Viable counts of M. tuberculosis H37Rv in 7H9 medium
without and with different concentrations of cefadroxil on days 0,
3 and 7
Conc. of Log10 cfu/ml on day BA
drug (µg/ml)     0 3 7
0 (control) 5.66 5.88 7.42 -
15 5.66 4.50 3.48 0.31
30 5.66 4.20 3.45 0.32
BA, bactericidal activity
Table II. MIC of cefadroxil against clinical isolates
Strains No. MIC (µg/ml) in 7H11 agar
tested
5 10 20 40 >40
H37Rv
(reference) 6 4 2 0 0 0
Clinical
(sensitive) 10 7 0 0 1 2
Clinical
(resistant) 19 7 2 1 1 8
60 INDIAN J MED RES, FEBRUARY 1997
penicillin G in the beta-lactamase assay as described
by Backelin et al 8. We found that the cefadroxil was
not hydrolysed by the cefadroxil sensitive and resis-
tant strains obtained in this study. This suggests that
mechanism(s) of resistance other than the inactiva-
tion of the drug might play a role in the cefadroxil
resistance in M. tuberculosis.
In the past many cephalosporins and penicillins,
which were approved for clinical use, were screened
for their activity against M. tuberculosis H37Rv9.
Over 600 derivatives of cephalosporin C were
screened for activity against M. tuberculosis H37Rv
and their structure-activity relationships were stud-
ied by Misiek et al  .10 As a consequence of the poor
activity displayed by these compounds, M. tubercu-
losis is generally not included in the screening of
new derivatives of cephalosporins for antimyco-
bacterial activity. However, availability of many beta-
lactamase resistant cephalosporins prompted many
workers to screen them against mycobacteria includ-
ing M. tuberculosis. Heifets et al 11 reported that
cephalosporins such as ceforanide, ceftozoxime,
cephapirin and cefataxime showed promise in their
activity against M. tuberculosis while, cefamandole
and cephalothin were ineffective.
In the present study about 60 per cent of the
clinical isolates of M. tuberculosis were inhibited at
a concentration of the drug which is less than the
peak plasma concentration attained in human beings
and about 50 per cent of the drug resistant isolates
were susceptible to this drug. In view of these find-
ings and considering the good pharmacokinetic char-
acteristics of cefadroxil,  in  vi tro studies on
synergestic action against M. tuberculosis of
cefadroxil with other antitubercular drugs, isoniazid
and rifampicin, and in vivo studies using mouse and
guineapig models might throw some insight into the
suitability of cefadroxil in the treatment of tubercu-
losis.
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